TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Quest Pharmatech ( (TSE:QPT) ) is now available.
Quest PharmaTech Inc. has announced the conversion of its bonds in OQP Bio Inc. into shares of OQPBIOM Inc., making it the largest shareholder with a 26.25% stake. This strategic move strengthens Quest’s position in the cancer immunotherapy market, as OQPBIOM Inc. develops immunotherapeutic products for cancer treatment. The company plans to engage an independent valuator to assess the value of these shares for future financial statements.
More about Quest Pharmatech
Quest PharmaTech Inc. is a publicly traded Canadian biopharmaceutical company focused on developing products to enhance quality of life. It holds a significant ownership in OncoQuest Inc., which previously sold its immunotherapy technology to a Korean company, and OncoVent, a joint venture in China developing cancer immunotherapeutics. Quest is also advancing its proprietary MAb AR 9.6 for cancer treatment.
Average Trading Volume: 89,641
Technical Sentiment Signal: Hold
Current Market Cap: C$5.92M
Find detailed analytics on QPT stock on TipRanks’ Stock Analysis page.